Drug Trial Radar · NCT03987295
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
Last checked: Nov 19, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Sep 27, 2019
Primary completion
Jun 5, 2024
Study completion Jun 5, 2024
Sponsor
- Lead sponsor
- Alector Inc.Industry
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- Jun 17, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.
Conditions
- Frontotemporal Dementia
Interventions
AL001Drug
60 mg/kg of AL001 every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Severity of TEAEsTime frame: 197 weeks
- Severity of Treatment-Related TEAEsTime frame: 197 weeks
- Any TEAE Leading to Study Drug DiscontinuationTime frame: 197 weeks
- Immunogenicity Antidrug Antibodies (ADA) TiterTime frame: 97 weeks
- Confirmatory Immunogenicity Antidrug Antibodies (ADA) ResponsesTime frame: 97 weeks
- Change From Baseline in Sheehan Suicidality Tracking ScaleTime frame: 197 weeks
Locations
12 sites in 6 countries. Site status is shown where the registry gives one.
UCSF
San Francisco, California
Mayo Clinic
Rochester, Minnesota
University of Pennsylvania
Philadelphia, Pennsylvania
The Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases UT Health San Antonio
San Antonio, Texas
Lawson Health Research Institute, St. Joseph's
London, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Technical University of Munich
München, Germany
University of Ulm
Ulm, Germany
University of Brescia
Brescia, Italy
Brain Research Center - PPDS
Amsterdam, Netherlands
Erasmus University Medical Center
Rotterdam, Netherlands
University College London
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.